The Scientist

» Elsevier

Most Recent

image: “WikiGate” Ruffles OA Feathers

“WikiGate” Ruffles OA Feathers

By | September 16, 2015

A partnership between Wikipedia and scholarly publishing behemoth Elsevier has open-access advocates up in arms.

0 Comments

image: Journal Price Tags Revealed

Journal Price Tags Revealed

By | June 18, 2014

Economists explore the wheelings and dealings of universities and publishers during largely secret negotiations regarding access to scientific journals.

0 Comments

image: Reading Into the Future

Reading Into the Future

By | April 1, 2012

Will traditional scientific journals follow newspapers into oblivion?

20 Comments

image: Opinion: Academic Publishing Is Broken

Opinion: Academic Publishing Is Broken

By | March 19, 2012

The current system by which academics publish their scientific discoveries is a massive waste of money.

100 Comments

image: Elsevier Abandons Anti-Open Access Bill

Elsevier Abandons Anti-Open Access Bill

By | February 28, 2012

The publishing giant withdraws its support of the Research Works Act, which would eliminate open-access requirements on federally funded work.

18 Comments

image: Occupy Elsevier?

Occupy Elsevier?

By | February 7, 2012

A boycott of the publishing giant swells, but is the criticism warranted?

100 Comments

Popular Now

  1. UC Berkeley Receives CRISPR Patent in Europe
    Daily News UC Berkeley Receives CRISPR Patent in Europe

    The European Patent Office will grant patent rights over the use of CRISPR in all cell types to a University of California team, contrasting with a recent decision in the U.S.

  2. DNA Replication Errors Contribute to Cancer Risk
  3. Should Healthy People Have Their Exomes Sequenced?
    Daily News Should Healthy People Have Their Exomes Sequenced?

    With its announced launch of a whole-exome sequencing service for apparently healthy individuals, Ambry Genetics is the latest company to enter this growing market. But whether these services are useful for most people remains up for debate.  

  4. Rethinking a Cancer Drug Target
    Daily News Rethinking a Cancer Drug Target

    The results of a CRISPR-Cas9 study suggest that MELK—a protein thought to play a critical role in cancer—is not necessary for cancer cell survival.

Business Birmingham